Pompe Disease
New Pompe disease research, summarized each month in plain language.
2026 so far: So far in 2026 (January 2026 to September 2026), real-world studies clarified how ERT results can vary based on when treatment starts and on antibodies. Early gene therapy reports and newer monitoring tools also appeared, but clinical signals were mixed and still limited. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Switching and comparing ERT. Comparative and switch data expanded, with benefits often modest.
- Early infant ERT timing. Timing signals strengthened, especially for infant heart outcomes.
- Antibodies and infusion reactions. Immune variability became more measurable, with antibody-linked effects.
- Supportive care updates. More studies documented real-life supports beyond enzyme choice.
- New monitoring tools. Candidate biomarkers and imaging expanded, with early validation signals.
New
September 2026
- Antibody effects. Very high antibodies were sometimes linked to less available enzyme.
- Diet add-on. A high-fat, higher-protein diet was feasible but unproven.
- Sleep breathing. Sleep breathing problems could appear despite stable daytime tests.
- Later seizures. Some early-treated children developed seizures after age 7.
August 2026
- Gene therapy effects. Muscle enzyme levels rose, but day-to-day gains varied.
- Breathing measures. Some breathing changes showed up on tests beyond spirometry.
- Chronic pain. Chronic muscle pain was common in adults and not linked to strength.
July 2026
- Enzyme switch outcomes. Walking often stayed stable or improved after switching enzymes.
- Breathing test results. Clinic breathing measures often changed little after switching therapy.
- Home infusion reactions. One pediatric cohort reported fewer reactions with home infusions.
- Muscle health test. A quick electrical test matched muscle imaging and motor function.
June 2026
- ERT in pregnancy. In one small review, ERT had no reported infusion reactions.
- Noninvasive ventilation. One adult case improved quickly after starting noninvasive ventilation.
- Low screen results. One gene pattern can lower enzyme screens without symptoms.
- Muscle fat on MRI. More muscle fat on imaging matched worse function over time.
May 2026
- Survival in routine care. Two real-world cohorts reported better survival in people who received enzyme replacement therapy than in those who did not.
- Infant heart measurements. In infants, heart measurements improved after about one year of enzyme replacement therapy.
- Antibodies and MRI monitoring. Antibody testing and MRI-based measures are being studied as monitoring tools, but their clinical value is not yet proven.
- Adult heart risk factors. Adults with late-onset Pompe disease had higher levels of several heart-risk factors than matched controls in one study.
April 2026
- Infusion reaction risk. In adults on enzyme replacement therapy, higher anti-drug antibody levels were linked with more infusion-related reactions.
- Early ERT in screened infants. In a small series of children found through newborn screening, early enzyme replacement therapy was reported alongside motor improvement.
- Follow-up after newborn screening. Newborn screening identified Pompe disease, but many initial positive results required additional testing and genetic interpretation to clarify the diagnosis.
March 2026
- Enzyme replacement results. In adults with late-onset Pompe disease, one year of standard enzyme replacement therapy was linked with better walking and some strength measures, while breathing change was not clearly improved in the same study.
- Next enzyme approaches. Newer enzyme programs and enzyme-protecting delivery approaches were discussed, but most evidence remained early-stage and results were mixed across measures.
- More sensitive monitoring. Wearables and more precise strength and balance tests detected subtle change over time, including changes that manual muscle testing may miss.
- Finding hidden genetic causes. More specialized genetic and RNA testing can sometimes identify a cause when standard testing does not.
February 2026
- Enzyme therapy results at 1 year. Across one-year trial comparisons, cipaglucosidase alfa plus miglustat more often showed better average walking and breathing outcomes than alglucosidase alfa, while real-world follow-up after switching was often described as stable.
- Markers that track change. Higher starting urinary Glc4 was linked to later decline in walking distance over four years, and small imaging studies measured diaphragm weakness more directly than routine tests.
- Genetic results need context. Large screening studies found many GAA gene variants (including newly described ones) and reinforced that some genetic findings still need enzyme testing to interpret.
- Home vs clinic infusion reactions. Pooled trial data showed similar infusion reaction rates for cipaglucosidase alfa plus miglustat given at home versus in a clinic.
January 2026
- Earlier infant treatment and heart change. In infantile-onset Pompe disease, starting enzyme replacement earlier was linked to faster improvement in heart measurements, although longer-term outcomes still varied between children.
- Antibodies to enzyme therapy. High antibody levels against the replacement enzyme were common in infant cohorts, including in some children who were not considered at the highest risk.
- Measuring brain and muscle effects. In infantile-onset disease, the blood marker GFAP tracked white matter changes on brain MRI, and in late-onset disease, quantitative thigh MRI measures matched overall severity.
Get the monthly update by email
Subscribe here to receive an email when a new monthly Pompe disease update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).